Seres Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Seres Therapeutics's estimated annual revenue is currently $155.3M per year.
- Seres Therapeutics's estimated revenue per employee is $329,660
- Seres Therapeutics's total funding is $402.8M.
- Seres Therapeutics's current valuation is $738.5M. (January 2022)
Employee Data
- Seres Therapeutics has 471 Employees.
- Seres Therapeutics grew their employee count by 0% last year.
Seres Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | EVP, Chief Financial Officer and Head Business Development | Reveal Email/Phone |
2 | CFO and Head Business Development | Reveal Email/Phone |
3 | VP | Reveal Email/Phone |
4 | VP, Corporate Controller | Reveal Email/Phone |
5 | Executive Assistant to the Chief Scientific Officer | Reveal Email/Phone |
6 | VP, CMC Technology Development | Reveal Email/Phone |
7 | VP Clinical Research | Reveal Email/Phone |
8 | VP, Talent Acquisition, HR Systems and People Analytics | Reveal Email/Phone |
9 | VP, People & Culture Partnership | Reveal Email/Phone |
10 | VP, Human Resources | Reveal Email/Phone |
Seres Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is Seres Therapeutics?
Seres Health is a clinical stage biotherapeutic company focused on discovering and developing Ecobiotic™ therapeutic products to treat important diseases by targeting the underlying biology of the human microbiome. Seres is pioneering the first therapeutics that catalyze a shift to health by augmenting the biology of the microbiome. Current candidates span metabolic, inflammatory, and infectious diseases.
keywords:N/A
$402.8M
Total Funding
471
Number of Employees
$155.3M
Revenue (est)
0%
Employee Growth %
$738.5M
Valuation
N/A
Accelerator
Seres Therapeutics News
Seres Therapeutics (NASDAQ:MCRB shareholders incur further losses as stock declines 14% this week, taking one-year losses to 74%. By: Simply...
Seres Therapeutics, Inc. (NASDAQ:MCRB) Receives Average Rating of Hold from Analysts. Posted by admin on Apr 19th, 2022.
Seres plots for a mid-year approval request for its C. difficile therapeutic, SER-109. Related: Seres Therapeutics' Oral Microbiome Candidate...
Press Release | Nov 10. 2021 07:07 GMT SER-109 has the potential to be the first-ever live biotherapeutic product (LBP) to be produced commercially; the collaboration with Seres Therapeutics is a critical milestone for Bacthera, a joint venture between a Lonza Group Affiliate and Chr. Hansen. ...
Other Companies in Cambridge
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | N/A | 473 | 7% | N/A |
#2 | $177.8M | 474 | 34% | N/A |
#3 | $102.6M | 475 | 17% | $70.6M |
#4 | $28.2M | 476 | 32% | $172M |
#5 | $62.1M | 487 | 6% | N/A |